Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 18;8(3):52.
doi: 10.3390/metabo8030052.

High-Throughput Direct Mass Spectrometry-Based Metabolomics to Characterize Metabolite Fingerprints Associated with Alzheimer's Disease Pathogenesis

Raúl González-Domínguez  1   2   3 , Ana Sayago  4   5 , Ángeles Fernández-Recamales  6   7
Affiliations
Review

High-Throughput Direct Mass Spectrometry-Based Metabolomics to Characterize Metabolite Fingerprints Associated with Alzheimer's Disease Pathogenesis

Raúl González-Domínguez et al. Metabolites. .

Abstract

Direct mass spectrometry-based metabolomics has been widely employed in recent years to characterize the metabolic alterations underlying Alzheimer's disease development and progression. This high-throughput approach presents great potential for fast and simultaneous fingerprinting of a vast number of metabolites, which can be applied to multiple biological matrices including serum/plasma, urine, cerebrospinal fluid and tissues. In this review article, we present the main advantages and drawbacks of metabolomics based on direct mass spectrometry compared with conventional analytical techniques, and provide a comprehensive revision of the literature on the use of these tools in the investigation of Alzheimer's disease.

Keywords: Alzheimer’s disease; biomarkers; direct mass spectrometry; metabolomics; pathogenesis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Advantages and drawbacks of DMS-based metabolomics compared with conventional hyphenated approaches.
See this image and copyright information in PMC

References

    1. González-Domínguez Á., Durán-Guerrero E., Fernández-Recamales Á., Lechuga-Sancho A.M., Sayago A., Schwarz M., Segundo C., González-Domínguez R. An overview on the importance of combining complementary analytical platforms in metabolomic research. Curr. Top. Med. Chem. 2017;17:3289–3295. doi: 10.2174/1568026618666171211144918. - DOI - PubMed
    1. González-Domínguez R., Sayago A., Fernández-Recamales Á. Metabolomics in Alzheimer’s disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2017;1071:75–92. doi: 10.1016/j.jchromb.2017.02.008. - DOI - PubMed
    1. González-Domínguez R., González-Domínguez Á., Sayago A., Fernández-Recamales Á. Mass spectrometry-based metabolomic multiplatform for Alzheimer’s disease research. In: Perneczky R., editor. Biomarkers for Alzheimer’s Disease Drug Development. Humana Press; New York, NY, USA: 2018. pp. 125–137. - DOI - PubMed
    1. Draper J., Lloyd A.J., Goodacre R., Beckmann M. Flow infusion electrospray ionisation mass spectrometry for high throughput, non-targeted metabolite fingerprinting: A review. Metabolomics. 2013;9:4–29. doi: 10.1007/s11306-012-0449-x. - DOI
    1. González-Domínguez R., Sayago A., Fernández-Recamales Á. Direct infusion mass spectrometry for metabolomic phenotyping of diseases. Bioanalysis. 2017;9:131–148. doi: 10.4155/bio-2016-0202. - DOI - PubMed

LinkOut - more resources